


PHARMACEUTICAL 2020

ORAMED PHARMACEUTICALS INC. Rank 164 of 362







PHARMACEUTICAL 2020

ORAMED PHARMACEUTICALS INC. Rank 164 of 362



The relative strengths and weaknesses of ORAMED PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ORAMED PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 120% points. The greatest weakness of ORAMED PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is -148%, being 155% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	33,324
Cost of Goods Sold	90
Intangible Assets	0
Liabilities, Current	5,308
Liabilities, Non-Current	9,962
Other Assets	1,315
Other Compr. Net Income	0
Other Expenses	785
Other Liabilities	0
Other Net Income	0
Property and Equipment	24
Research and Development	13,522
Revenues	3,764
Selling, General and Administrative Expense	3,722

Output Variable	Value in 1000 USD
Assets	34,663
Liabilities	15,270
Expenses	18,119
Stockholders Equity	19,393
Net Income	-14,355
Comprehensive Net Income	-14,355
Economic Capital Ratio	-148%